A specialist R&D company developing next-generation trace chemical detection and breath-based diagnostic instruments. We combine proprietary detection technology, AI inference, and instrument engineering to solve detection problems conventional technology cannot.
AATG LLC is a focused specialist R&D company headquartered in New Jersey. The founder has close to 30 years of combined experience in field threat detection, trace chemical sensing, and defense instrument development.
The instruments operators and clinicians depend on in life-safety situations must be better than what is currently available. We build technology that closes the gap between what is needed and what exists — not by incremental improvement of existing designs, but by applying a fundamentally different approach.
We do not build products that are "good enough." We build products that close a documented, consequential capability gap using defensible, peer-reviewed science as the foundation — and then subject those claims to rigorous validation before any government or clinical customer commitment.
Every design decision starts with what the operational scenario actually requires. We choose methods that fit the problem — not the ones that are most familiar. Where that leads to unconventional approaches, we document the reasoning and subject it to adversarial review.
We do not make performance claims until we have data. Sensitivity claims in our publications and briefings are anchored to peer-reviewed published results. Where empirical data does not yet exist, we say so explicitly — and describe the validation plan that will generate it.
Our proprietary AI inference architecture was not designed for defense and then applied to medicine. It was validated independently in a demanding clinical VOC detection application before being brought to the CWA detection problem. Real-world cross-domain performance is the strongest evidence that the science is real.
Each competency reflects sustained investment over many years — not recently acquired for a specific program, but developed as core organizational capability.
Deep expertise in proprietary detection technology and sensing for trace gas detection, including sample handling and advanced signal processing. Detection methodology grounded in published, peer-reviewed research.
Design and implementation of proprietary AI inference engines for chemical identification under open-world conditions. Calibrated confidence scoring, mixture analysis, and unknown compound characterization — capabilities conventional chemometric methods cannot provide.
Nearly three decades in CWA detection methodology, instrument characterization, and field deployment. Prior collaboration with researchers at Edgewood Chemical Biological Center (ECBC). Deep understanding of the operational constraints laboratory instruments do not model.
Validated methodology for detecting volatile organic compound (VOC) biomarkers in exhaled breath for cancer diagnostics. The breath matrix — complex, variable, biologically meaningful — is a more demanding analytical challenge than field air sampling, and validates the same detection architecture deployed in our defense platform.
Full-stack hardware development from bench assembly through production prototype: sensor assembly, sample preparation, and embedded electronics and firmware. Specific expertise in size, weight, and power optimization for handheld and UAV-payload applications.
Familiarity with SBIR/STTR program structure and application requirements. Experience with government technical review and documentation standards. Understanding of CWMD and MCDC consortium engagement pathways and their validation requirements.
Everything we present to government customers and technical reviewers is grounded in documented, independently verifiable work.
Edgewood Chemical Biological Center. Prior research collaboration with ECBC scientists on CWA detection methodology. This work, reflected in publications and field detection reference materials, provides the government-validated scientific foundation for the r-Guard™ detection approach. Full details available to qualified partners under NDA.
Author of Detection Technologies for Chemical Warfare Agents and Toxic Vapors (CRC Press) and Field Detection Technologies for Explosives (International Labmate), co-authored with ECBC researchers. Sensitivity claims traceable to published experimental data — not internal projections. Reference list available under NDA.
The proprietary AI inference architecture was independently validated in a demanding clinical VOC detection application before r-Guard™ development began. This cross-domain validation is the strongest evidence of real-world AI performance.
SBIR Phase I/II applications actively being prepared targeting DoD CWMD and related programs. MCDC consortium engagement planned. Government acquisition pathway well understood.
The same proprietary detection architecture drives both AATG product platforms — validated cross-domain, de-risked by design.
Field-deployable chemical warfare agent detector. Continuous screening and on-site confirmation in one handheld unit — exceptional sensitivity (ppb to sub-ppb, pg to ng range). No carrier gas. No radioactive source. Continuous monitoring with no detection gaps, and AI-powered identification with calibrated confidence scores.
Explore r-Guard™ →Breath-based cancer diagnostic system for lung and breast cancer early detection. Detects volatile organic compound (VOC) biomarkers in exhaled breath using the same proprietary detection methodology — the operational clinical validation proving the underlying science works in a demanding real-world environment.
Explore BreathDX™ →Proprietary detection technology — exceptional sensitivity, ppb to sub-ppb.
Proprietary sample preparation — no carrier gas, no cylinders.
Probabilistic identification with calibrated confidence scoring.
We are structured to engage with government program offices, defense primes, and investment partners through established formal pathways.
Detection methodology, instrument configuration, signal processing architecture, and AI inference pipeline are IP protected. Full technical specifications available to qualified partners under executed NDA.
Phase I/II applications in preparation targeting DoD CWMD, DHS S&T, and related federal programs. We are prepared to engage program officers and technical evaluators at any stage.
Consortium engagement with the Chemical and Biological Defense (CBD) program and MCDC is planned. r-Guard™ addresses documented CBRNE capability gaps consistent with stated DoD technology priority areas.
Full technical documentation — instrument architecture, sensitivity data, AI methodology, and experimental validation results — is available to qualified partners under a standard mutual NDA. Contact us to initiate.
Open to licensing, co-development, and integration partnerships with defense primes seeking to add CWA detection capability to existing platforms. Designed for integration into UAV/UGV payloads and fixed-site monitoring systems.
Actively seeking co-founders with detection instrument hardware, precision engineering, or medical device backgrounds. If you have the technical depth to build what we have designed, we want to talk — specific requirements shared under NDA.
We welcome inquiries from government program officers, defense prime contractors, UAV platform integrators, clinical research partners, and potential co-founders. Full technical documentation available under NDA.